Workflow
BERRY GENOMICS(000710)
icon
Search documents
医疗服务行业周报2.2-2.6:互联网医疗首诊破冰,关注专科连锁龙头-20260208
Xiangcai Securities· 2026-02-08 08:24
Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for investment opportunities in this sector [10][64]. Core Insights - The medical services sector has shown resilience, with a recent increase in the sector's PE ratio to 34.43X and PB ratio to 3.49X, indicating a positive trend in valuation metrics [4][29]. - The approval of internet medical first diagnosis trials in Beijing marks a significant regulatory breakthrough, potentially accelerating the online medical service process and providing new market opportunities for private medical institutions [5][62][63]. - The report highlights the importance of digital regulation and standardization in enhancing service capabilities for private medical institutions, particularly in consumer healthcare sectors like pediatrics and dermatology [5][62]. Summary by Sections Industry Performance - The pharmaceutical and biological sector increased by 0.14%, ranking 15th among 31 primary industries, outperforming the Shanghai Composite Index by 1.47 percentage points [2][12]. - The medical services sub-sector reported a 1.31% increase, closing at 6827.17 points, with a year-to-date performance of 41.41% [24][27]. Company Performance - Top-performing companies in the medical services sector include Meidisi (+18.0%), Tongce Medical (+8.1%), and Nuosige (+5.7%), while underperformers include Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.56X from the previous week, while the PB ratio has risen by 0.06X, indicating a strengthening in market confidence [4][29]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing sector, as well as companies like WuXi AppTec and Haoyuan Pharmaceutical [10][64]. - It also recommends monitoring private medical service providers with compliance experience, such as Aier Eye Hospital, as they are expected to benefit from the evolving regulatory landscape [5][64].
贝瑞基因(000710.SZ):预计2025年净亏损1.70亿元—2.50亿元
Ge Long Hui A P P· 2026-01-30 00:36
Core Viewpoint - Berry Genomics (000710.SZ) forecasts a net loss of 170 million to 250 million yuan for the fiscal year 2025, compared to a loss of 192 million yuan in the same period last year [1] Financial Performance - The company's net profit attributable to shareholders is expected to be a loss of 170 million to 250 million yuan, with a non-GAAP net profit loss of 165 million to 245 million yuan, both reflecting a decline from the previous year's loss of 192 million yuan [1] Revenue and Cash Flow - Revenue has declined due to factors such as a decrease in birth rates, although operating cash flow remains stable [1] Asset Management - The company has conducted a comprehensive review and impairment testing of various assets based on the principle of prudence, which has impacted the net profit for the reporting period [1] Research and Development - Berry Genomics has increased its R&D investment and is actively expanding its product lines, leading to enhanced capabilities in third-generation gene sequencing technology, which has also affected the current net profit due to high R&D expenses [1] Strategic Initiatives - The company is focusing on integrating gene testing technology with artificial intelligence algorithms to promote innovation in precision medicine, which has generated some revenue [1] Business Development - The newborn gene screening business is progressing as expected, which is anticipated to have a significant positive impact on the company's business layout in the reproductive health sector [1]
贝瑞基因:2025年扣非后净利润预亏1.65亿元至2.45亿元
Zhong Zheng Wang· 2026-01-29 12:28
Core Viewpoint - The company, Berry Genomics, anticipates a net loss for 2025, projecting a net profit attributable to shareholders between -250 million to -170 million yuan, compared to -192 million yuan in 2024 [1][2] Financial Performance - The company expects a net loss of 165 million to 245 million yuan after deducting non-recurring items for 2025, with a corresponding loss of 192 million yuan in 2024 [1] - Revenue has declined during the reporting period, although operating cash flow remains stable [1] Asset Management - Berry Genomics has conducted a comprehensive review and impairment testing of its assets based on prudence, which has impacted the current net profit [1] - The company has increased its R&D investment, which has led to higher expenses affecting the current net profit [1] Business Focus - The main business of Berry Genomics includes gene testing services and related equipment, focusing on reproductive health, genetic disease testing, and technology services [1] - The company aims to integrate gene testing technology with artificial intelligence algorithms to drive innovation in precision medicine, which is expected to generate revenue [2] Market Position - The newborn gene screening business is progressing as expected, which is anticipated to positively impact the company's business layout in reproductive health [2] - From 2021 to 2024 and the first three quarters of 2025, the company's net profit, net profit attributable to shareholders, and net profit after deducting non-recurring items have consistently been negative [2] Shareholder Issues - Recently, the controlling shareholder, Gao Yang, faced a default in stock pledge repurchase business, resulting in the forced execution of 3.5352 million shares, accounting for 0.999% of the company's total share capital [2]
贝瑞基因:预计2025年净利润为-1.7亿元至-2.5亿元
Xin Lang Cai Jing· 2026-01-29 08:46
贝瑞基因公告,预计2025年度净利润为负,预计为-2.5亿元至-1.7亿元。报告期内,受生育下降等因素 影响,公司营业收入有所下滑,经营性现金流保持平稳水平。根据会计准则要求,公司基于谨慎性原则 对各类资产进行全面检查和减值测试,谨慎计提各项资产减值,对报告期净利润产生了一定影响。 ...
贝瑞基因(000710) - 2025 Q4 - 年度业绩预告
2026-01-29 08:40
Financial Performance - The company expects a net profit in the range of -25,000 to -17,000 thousand yuan for the fiscal year 2025, compared to a net profit of -19,242.85 thousand yuan in the previous year[5]. - The net profit excluding non-recurring gains and losses is projected to be between -24,500 and -16,500 thousand yuan, compared to -19,219.19 thousand yuan in the same period last year[5]. - The basic earnings per share are expected to be between -0.71 and -0.48 yuan, compared to -0.54 yuan in the previous year[5]. - Non-recurring gains and losses are estimated to impact net profit by approximately 5,000 thousand yuan, compared to 240 thousand yuan in the same period last year[4]. - The company has conducted a comprehensive review and impairment testing of various assets, which has also affected the net profit for the reporting period[4]. - Investors are advised to note that the financial data is based on preliminary calculations and the final figures will be disclosed in the 2025 annual report[6]. Revenue and Market Factors - The decline in revenue is attributed to factors such as a decrease in birth rates, while operating cash flow remains stable[4]. - The newborn genetic screening business is progressing as expected, which is anticipated to positively impact the company's business layout in reproductive health[4]. Research and Development - The company has increased its R&D investment, which has impacted the current net profit due to high phase expenditures[4]. - The integration of genetic testing technology with artificial intelligence algorithms is expected to drive innovation in precision medicine and generate revenue[4].
贝瑞基因:公司深耕生育健康领域多年
Zheng Quan Ri Bao· 2026-01-26 13:44
证券日报网讯 1月26日,贝瑞基因在互动平台回答投资者提问时表示,国家优生优育相关政策的推进, 将进一步扩大生育健康检测市场需求,对公司核心业务发展具有积极促进作用。公司深耕生育健康领域 多年,布局孕前、产前、新生儿三级预防体系,未来公司将凭借先进的检测技术、完善的产品体系以及 广泛的医院合作网络,积极把握市场机遇,助力出生缺陷防控工作。 (文章来源:证券日报) ...
贝瑞基因今日大宗交易折价成交271.87万股,成交额3229.82万元
Xin Lang Cai Jing· 2026-01-26 08:51
| 权益类证券大宗交易(协议交易) | | | | | | | 0 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | | | | (元) | (万股/万份) | (万元) | | | | 2026-01-26 | 000710 | 贝瑞基因 | 11.88 | 271.87 | | 3,229.2国泰海通证券股份 | 江海证券有限公司 | | | | | | | | 有限公司瑞安莘阳 | 上海万航渡路证券 | 1月26日,贝瑞基因大宗交易成交271.87万股,成交额3229.82万元,占当日总成交额的9.36%,成交价 11.88元,较市场收盘价13.31元折价10.74%。 ...
医疗服务板块1月22日跌0.25%,诚达药业领跌,主力资金净流出3.13亿元
Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]
贝瑞基因股价跌5.33%,永赢基金旗下1只基金位居十大流通股东,持有152.68万股浮亏损失109.93万元
Xin Lang Cai Jing· 2026-01-16 03:00
Group 1 - Berry Genomics experienced a decline of 5.33% on January 16, with a stock price of 12.78 CNY per share, a trading volume of 288 million CNY, a turnover rate of 6.64%, and a total market capitalization of 4.518 billion CNY [1] - The company, established on April 14, 1997, and listed on April 22, 1997, is based in Beijing and specializes in high-throughput sequencing technology for genetic testing, along with the sale of equipment and reagents [1] - The revenue composition of Berry Genomics includes reagent sales at 45.74%, medical testing services at 31.24%, basic research services at 18.33%, equipment sales at 3.48%, and other sources at 1.20% [1] Group 2 - The top circulating shareholder data indicates that a fund under Yongying Fund ranks among the top shareholders of Berry Genomics, with the Medical Device ETF (159883) newly entering the top ten shareholders in the third quarter, holding 1.5268 million shares, which accounts for 0.46% of circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion CNY, yielding 11.25% this year, ranking 708 out of 5531 in its category, and achieving a 17.13% return over the past year, ranking 3570 out of 4215 [2] - The fund has experienced a cumulative loss of approximately 45.72% since its inception [2]
精准医疗板块1月15日跌1.44%,贝瑞基因领跌,主力资金净流出8.7亿元
Sou Hu Cai Jing· 2026-01-15 09:06
Market Overview - The precision medicine sector experienced a decline of 1.44% on January 15, with Berry Genomics leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] Stock Performance - Notable gainers in the precision medicine sector included: - Ruian Gene (688217) with a closing price of 32.51, up 1.82% [1] - Zhaoli Pharmaceutical (300181) with a closing price of 17.08, up 1.07% [1] - Rendu Biotech (688193) with a closing price of 51.65, up 0.68% [1] - Significant decliners included: - Berry Genomics (000710) with a closing price of 13.50, down 10.00% [2] - BGI Genomics (300676) with a closing price of 56.90, down 3.97% [2] - Union Medical (688271) with a closing price of 139.60, down 3.64% [2] Capital Flow - The precision medicine sector saw a net outflow of 870 million yuan from institutional investors, while retail investors had a net inflow of 1.179 billion yuan [2][3] - The capital flow for key stocks showed: - WuXi AppTec (603259) had a net inflow of 42.33 million yuan from institutional investors [3] - Ruian Gene (688217) experienced a net outflow of 7.04 million yuan from institutional investors [3] - ST Xiangxue (300147) had a net inflow of 4.43 million yuan from institutional investors [3]